Pfizer Lung Cancer Drug to Get Priority Review – Xconomy

by lowes1 on May 21, 2011


InPharm
Pfizer Lung Cancer Drug to Get Priority Review
Xconomy
New York-based Pfizer (NYSE: PFE) announced that it has simultaneously applied for approval of its lung cancer drug, crizotinib, in the US and Japan, and that the FDA granted it priority review. Crizotinib is the first in a new class of drugs called
Pfizer accelerates Crizotinib regulatory proceduresPharmaceutical Business Review
FDA Grants Pfizer Priority Review For Lung Cancer DrugMyStateline.com
Pfizer lung cancer drug – Is FDA becoming more Open to Experimental Therapies?Gerson Lehrman Group
Investor’s Business Daily -WKZO -Pharma Times
all 78 news articles »

View full post on lung cancer – Google News

Leave a Comment

Previous post:

Next post: